Immunic, Inc. (NASDAQ:IMUX) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX) have received an average recommendation of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $11.80.

IMUX has been the subject of several recent analyst reports. HC Wainwright initiated coverage on shares of Immunic in a report on Monday, November 25th. They issued a “buy” rating and a $10.00 price target for the company. Leerink Partners reissued an “outperform” rating and issued a $5.00 price target on shares of Immunic in a report on Monday, September 9th. EF Hutton Acquisition Co. I raised shares of Immunic to a “strong-buy” rating in a report on Monday, September 16th. Leerink Partnrs raised shares of Immunic to a “strong-buy” rating in a report on Monday, September 9th. Finally, StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th.

Insider Activity at Immunic

In other news, Director Richard Alan Rudick acquired 87,300 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was purchased at an average price of $1.15 per share, with a total value of $100,395.00. Following the completion of the acquisition, the director now owns 87,300 shares of the company’s stock, valued at $100,395. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 3.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Immunic

Hedge funds have recently modified their holdings of the company. Virtu Financial LLC purchased a new stake in shares of Immunic in the third quarter valued at about $50,000. Jane Street Group LLC grew its holdings in shares of Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after purchasing an additional 38,553 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its position in Immunic by 70.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after buying an additional 42,383 shares during the last quarter. Finally, State Street Corp lifted its position in Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after buying an additional 11,642 shares during the last quarter. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Stock Performance

Shares of NASDAQ IMUX opened at $1.09 on Wednesday. The firm has a market cap of $98.19 million, a PE ratio of -0.89 and a beta of 1.89. The firm has a fifty day moving average of $1.26 and a 200 day moving average of $1.33. Immunic has a one year low of $0.97 and a one year high of $2.11.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.